NCT00815711 is a clinical trial in Lung Disease, Interstitial, sponsored by Ohio State University.

Who is sponsoring NCT00815711?

NCT00815711 is sponsored by Ohio State University.

What condition does NCT00815711 study?

NCT00815711 studies Lung Disease, Interstitial, Idiopathic Pulmonary Fibrosis.

Is NCT00815711 still recruiting?

NCT00815711 is currently completed. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT00815711

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Idiopathic Pulmonary Fibrosis Registry for Future Studies

Completed Last updated 8 November 2021

What this trial tests

trial in Lung Disease, Interstitial in 13 participants. Completed in 10 June 2015.

Timeline

1 December 2008

Primary endpoint
10 June 2015

10 June 2015

Quick facts

Lead sponsor	Ohio State University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	13
Start date	1 December 2008
Primary completion	10 June 2015
Estimated completion	10 June 2015
Sites	1 location across United States

Conditions studied

Lung Disease, Interstitial — all drugs for Lung Disease, Interstitial →
Idiopathic Pulmonary Fibrosis — all drugs for Idiopathic Pulmonary Fibrosis →

Sponsor

Ohio State University

Who can join

18 and older, any sex, with Lung Disease, Interstitial or Idiopathic Pulmonary Fibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To establish a registry of patients for future studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Ohio State University trials

Trials by the same sponsor.

NCT06542458 — Under-Represented Communities Diagnosed With SCD or MCI Through Tele-Cog · not yet recruiting
NCT07217548 — Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients · NA · enrolling by invitation
NCT07215221 — Implementation of TBI-RECOVER in Substance Use Treatment · NA · not yet recruiting
NCT07278427 — Reducing Parental Substance Use and Enhancing Family Resilience Among Rural Families Through Ohio START · recruiting
NCT07490444 — Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00815711 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ohio State University
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00815711.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing